Adding concomitant and adjuvant temozolomide to radiotherapy does not reduce health-related quality of life in people with glioblastoma

Cancer Treatment Reviews

Volumn 32, Issue 6, 2006, Pages 483-486

  Hamilton, David A ^a  

^a WELLINGTON HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; TEMOZOLOMIDE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; GLIOBLASTOMA; HUMAN; OUTCOME ASSESSMENT; PATIENT SELECTION; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE; SCORING SYSTEM;

EID: 33748126184     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.04.002     Document Type: Note

References (5)

1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352 (2005) 987-996
2. Efficace F., and Bottomley A. Assessing HRQOL: a neglected issue for high-grade glioma. Lancet Oncol 4 (2003) 11-12
3. Roa W., Brasher P.M., Bauman G., et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22 (2004) 1583-1588
4. Sneeuw K.C., Aaronson N.K., Osoba D., et al. The use of significant others as proxy raters of the quality of life of patients with brain cancer. Med Care 35 (1997) 490-506
5. Osoba D., Brada M., Yung W.K., and Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 18 (2000) 1481-1491